Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt.
Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Rheumatol Int. 2022 Jun;42(6):989-998. doi: 10.1007/s00296-022-05130-3. Epub 2022 Apr 16.
The study aimed to explore the experience of coronavirus disease-2019 (COVID-19) infection and vaccine adverse events (AEs) among rheumatologists. A validated questionnaire was distributed as a Google form to rheumatologists across the country via social networking sites from late December 2021 till early January 2022. The questionnaire included questions regarding participants' socio-demographic details, COVID-19 infection and vaccination details with special emphasis on AEs. Out of 246 responses, 228 were valid. 200 (81.3%) responders had received the vaccine. The mean age of the 228 participants was 37.9 ± 8.5 years, 196 were females and 32 males (F:M 6.1:1) from 18 governorates across the country. Comorbidities were present in 54 subjects (27%). There was a history of highly suspicious or confirmed COVID-19 infection in 66.7% that were all managed at home. The COVID-19 vaccine was received by 200 and a booster dose of 18.5%. Obesity and musculoskeletal involvement co-morbidities were present only in those with AEs (9.1% and 5.5% respectively). AEs were present in 82%; 66.7% had injection-site tenderness, 50% fatigue, 35.5% fever, 15% chills, 42.5% myalgia, 14.5% arthralgia, 8% low back pain, headache 31%, dizziness 10%, sleepliness 16% and 15% developed post-vaccine. There were no differences according to the geolocation regarding the occurrence of COVID-19 infection (p = 0.19) or AEs post-vaccine (p = 0.58). The adverse events were mostly mild to moderate and tolerable which makes this work in agreement with other studies that support the broad safety of the vaccine in favor of the global benefit from mass vaccination.
这项研究旨在探讨风湿科医生对 2019 年冠状病毒病（COVID-19）感染和疫苗不良反应（AE）的体验。2021 年 12 月底至 2022 年 1 月初，通过社交网站向全国各地的风湿病医生分发了一份经过验证的问卷，该问卷采用 Google 表单的形式。问卷包括有关参与者社会人口统计学细节、COVID-19 感染和疫苗接种细节的问题，特别强调了 AE。在 246 份回复中，有 228 份有效。200 名（81.3%）应答者已接种疫苗。228 名参与者的平均年龄为 37.9 ± 8.5 岁，来自全国 18 个省的 196 名女性和 32 名男性（女性：男性为 6.1:1）。54 名患者存在合并症（27%）。有 66.7%的人有高度可疑或确诊的 COVID-19 感染史，均在家中管理。200 人接种了 COVID-19 疫苗，其中 18.5%接受了加强针。肥胖和肌肉骨骼受累合并症仅见于有 AE 的患者（分别为 9.1%和 5.5%）。82%的人出现了 AE；66.7%的人出现注射部位压痛，50%的人出现疲劳，35.5%的人出现发热，15%的人出现寒战，42.5%的人出现肌痛，14.5%的人出现关节痛，8%的人出现腰痛，31%的人出现头痛，10%的人出现头晕，16%的人出现嗜睡，15%的人出现疫苗接种后乏力。根据地理位置，COVID-19 感染（p = 0.19）或疫苗接种后 AE（p = 0.58）的发生率无差异。不良反应大多为轻度至中度，可耐受，这与其他支持疫苗广泛安全性、有利于全球大规模接种获益的研究结果一致。
